MedTrace Logo

Effects of Plasmalogen on Obese Subjects

NCT03295188 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2019-02-19

No results posted yet for this study

Summary

This is a 12-week, randomized, double-blind, placebo-controlled study to evaluate the effects of scallop-derived plasmalogen on brain fatigue, body weight and changes in blood plasmalogen in obese subjects aged 20-75 years old.

Conditions

Interventions

DIETARY_SUPPLEMENT

Plasmalogen

Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.

DIETARY_SUPPLEMENT

Placebo

Placebo Group takes two placebo capsules per day for 12 weeks.

Sponsors & Collaborators

  • Japanese Plasmalogen Society

    lead OTHER

Principal Investigators

  • Takehiko Fujino · BOOCS Clinic Fukuoka

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-08
Primary Completion
2018-08-22
Completion
2018-08-22

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03295188 on ClinicalTrials.gov